Effectiveness of Bupropion for Treating Nicotine Dependence in Young People
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Little is known about the best ways to help young people stop smoking. Bupropion (a medication marketed as Wellbutrin or Zyban) has proved helpful in treating adult smokers. The purpose of this study is to determine if bupropion is also effective in treating smokers between the ages of 12 and 25 years old. This study also compares the effectiveness of bupropion used as a supplement to behavioral treatment versus behavioral treatment used alone. In addition, the study evaluates whether hormonal response to stress measured prior to the start of treatment predicts whether individuals respond well to treatment with medication.
| Condition | Intervention | Phase |
|---|---|---|
|
Tobacco Use Cessation Tobacco Use Disorder |
Drug: Bupropion Drug: Placebo Behavioral: CBT Treatment |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Stress Response and Smoking Cessation in Depressed Youth |
- Smoking Behavior [ Time Frame: nine weeks; six month post treamtent ] [ Designated as safety issue: No ]
- Withdrawal symptoms [ Time Frame: nine weeks; six month post treatment ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 150 |
| Study Start Date: | May 2004 |
| Estimated Study Completion Date: | December 2010 |
| Estimated Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Participants who will be placed in the active medication treatment group
|
Drug: Bupropion
150mg tablets taken orally twice daily.
|
|
Placebo Comparator: 2
Participants who will be placed in the placebo treatment group
|
Drug: Placebo
Participants will receive placebo in this treatment group.
|
|
Experimental: 3
Participants who will receive cognitive behavioral treatment only
|
Behavioral: CBT Treatment
Participants will undergo nine weeks of behavioral modification therapy only.
|
Detailed Description:
Cigarette smoking and other forms of tobacco exposure are one of the leading preventable causes of morbidity and mortality in the United States. Most smokers begin smoking during adolescence, and though they seem motivated to quit smoking, they frequently fail. Although behavioral treatments are available, they have not been very successful in past studies.
Depressed adults may have more difficulty quitting smoking than non depressed adults; this finding may also apply to depressed youth. The purpose of this study is to determine the effectiveness of bupropion in combination with standard behavioral treatment in helping young smokers quit, as compared to behavioral treatment alone. Finally, the study examines whether hormonal response to stress measured prior to treatment initiation predicts whether individuals respond well to treatment with bupropion.
Participants in this double-blind study will be randomly assigned to receive either bupropion or placebo. Both groups will receive behavioral treatment. The trial will last for 9 weeks, with weekly study visits. Study visits will last 30 minutes to 1 hour and will include medication monitoring, self-reported and biological measures of smoking, and behavioral treatment. Participants will have follow-up visits six months after completion of treatment and at yearly intervals for up to 4 years.
Eligibility| Ages Eligible for Study: | 12 Years to 25 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Has smoked at least 10 cigarettes each day for 3 or more months
- Weighs at least 90 lbs
- Motivated to quit smoking and has had at least one previous failed attempt
- Speaks, reads, and writes English
- Either diagnosed as depressed OR no history of a psychiatric disorder
Exclusion Criteria:
- History of bipolar disorder, eating disorder, schizophrenia, schizoaffective disorder, autism, or non-nicotine substance use disorder in the 6 months prior to study entry
- Currently suicidal or with a history of a suicide attempt in the 6 months prior to study entry
- Psychotic symptoms
- Use of psychotropic medication(s)
- Serious medical condition
- Prior use of bupropion for smoking cessation
- Currently using other smoking cessation treatments
Contacts and Locations| Contact: Kathryn Mettman | 214-648-5250 | kathryn.mettman@utsouthwestern.edu |
| United States, Texas | |
| University of Texas Southwestern Medical Center | Recruiting |
| Dallas, Texas, United States, 75390 9101 | |
| Contact: Kathryn Mettman 214-648-5250 teenhealth@utsouthwestern.edu | |
| Principal Investigator: | Uma Rao, MD | University of Texas Medical Center |
More Information
No publications provided
| Responsible Party: | Dr. Uma Rao, M.D., University of Texas Southwestern Medical Center |
| ClinicalTrials.gov Identifier: | NCT00129272 History of Changes |
| Other Study ID Numbers: | NIDA-15131-1, R01-15131-1, DPMC |
| Study First Received: | August 4, 2005 |
| Last Updated: | September 2, 2009 |
| Health Authority: | United States: Federal Government |
Additional relevant MeSH terms:
|
Tobacco Use Disorder Substance-Related Disorders Mental Disorders Bupropion Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Central Nervous System Agents |
Therapeutic Uses Pharmacologic Actions Dopamine Uptake Inhibitors Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Neurotransmitter Uptake Inhibitors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 18, 2013